A Heat Shock Protein 70-based Vaccine with Enhanced Immunogenicity for Clinical Use

Overview

Journal J Immunol

Specialty Allergy & Immunology

Date 2009 Dec 2

PMID 19949080

Citations 48

Authors

Jianlin Gong

Yunfei Zhang

John Durfee

Desheng Weng

Chunlei Liu

Shigeo Koido

Baizheng Song

Vasso Apostolopoulos

Stuart K Calderwood

Affiliations

Soon will be listed here.

Abstract

In previous studies, we have shown that heat shock protein 70-peptide complexes (HSP70.PCs) derived from the fusion of dendritic cells (DCs) to tumor cells (HSP70.PC-F) possess superior properties compared with HSP70.PCs from tumor cells. HSP70.PC-F are more effective in stimulation of DC maturation and induction of CTL that are able to provide protection of mice against challenge with tumor cells. To develop an improved formulation of HSP70.PC-based tumor vaccine for patient use, we extracted HSP70.PC-F from DCs fused to patient-derived ovarian cancer cells or established human breast cancer cells and examined their properties as tumor vaccines. HSP70.PC-F induced T cells that expressed higher levels of IFN-gamma and exhibited increased levels of killing of tumor cells, compared with those induced by HSP70.PC derived from tumor cells. Enhanced immunogenicity of HSP70.PC-F was associated with improved composition of the vaccine, including increased content of tumor Ags and their processed intermediates, and the detection of other heat shock proteins (HSPs) such as HSP90 and HSP110. The present study has therefore provided an alternative approach to preparation of HSP-based vaccines using DC/tumor fusion technology and gentle and rapid isolation of HSP peptide complexes.

Citing Articles

Efficacy of novel allogeneic cancer cells vaccine to treat colorectal cancer.

Alzeeb G, Tortorelli C, Taleb J, De Luca F, Berge B, Bardet C Front Oncol. 2024; 14:1427428.

PMID: 39114302 PMC: 11303197. DOI: 10.3389/fonc.2024.1427428.

Fusion of NY-ESO-1 epitope with heat shock protein 70 enhances its induced immune responses and antitumor activity against glioma .

Chen Y, Zheng L, Hua W, Wang J, Chen L, Huang A Transl Cancer Res. 2024; 13(1):191-201.

PMID: 38410235 PMC: 10894325. DOI: 10.21037/tcr-23-1476.

Crossroad between the Heat Shock Protein and Inflammation Pathway in Acquiring Drug Resistance: A Possible Target for Future Cancer Therapeutics.

Somu P, Basavegowda N, Gomez L, Jayaprakash H, Puneetha G, Yadav A Biomedicines. 2023; 11(10).

PMID: 37893013 PMC: 10604354. DOI: 10.3390/biomedicines11102639.

Hsp70, in Combination with IL-15 and PD-1 Blocker, Interferes with The Induction of Cytotoxic NK Cells in Relapsed Acute Myeloid Leukemia Patients.

Firouzi J, Hajifathali A, Azimi M, Parvini N, Ghaemi F, Asl N Cell J. 2023; 25(2):92-101.

PMID: 36840455 PMC: 9968373. DOI: 10.22074/cellj.2023.561054.1123.

The Chaperone System in Breast Cancer: Roles and Therapeutic Prospects of the Molecular Chaperones Hsp27, Hsp60, Hsp70, and Hsp90.

Alberti G, Vergilio G, Paladino L, Barone R, Cappello F, de Macario E Int J Mol Sci. 2022; 23(14).

PMID: 35887137 PMC: 9324353. DOI: 10.3390/ijms23147792.

References

Oki Y, McLaughlin P, Fayad L, Pro B, Mansfield P, Clayman G . Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer. 2006; 109(1):77-83. DOI: 10.1002/cncr.22389. View

Blachere N, Udono H, Janetzki S, Li Z, Heike M, Srivastava P . Heat shock protein vaccines against cancer. J Immunother Emphasis Tumor Immunol. 1993; 14(4):352-6. DOI: 10.1097/00002371-199311000-00016. View

Lindquist S, Craig E . The heat-shock proteins. Annu Rev Genet. 1988; 22:631-77. DOI: 10.1146/annurev.ge.22.120188.003215. View

Stevenson M, Calderwood S . Members of the 70-kilodalton heat shock protein family contain a highly conserved calmodulin-binding domain. Mol Cell Biol. 1990; 10(3):1234-8. PMC: 361007. DOI: 10.1128/mcb.10.3.1234-1238.1990. View

Enomoto Y, Bharti A, Khaleque A, Song B, Liu C, Apostolopoulos V . Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells. J Immunol. 2006; 177(9):5946-55. DOI: 10.4049/jimmunol.177.9.5946. View

Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov A, Gorelov S . An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008; 372(9633):145-154. DOI: 10.1016/S0140-6736(08)60697-2. View

Ueda G, Tamura Y, Hirai I, Kamiguchi K, Ichimiya S, Torigoe T . Tumor-derived heat shock protein 70-pulsed dendritic cells elicit tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity. Cancer Sci. 2004; 95(3):248-53. PMC: 11158815. DOI: 10.1111/j.1349-7006.2004.tb02211.x. View

Murshid A, Gong J, Calderwood S . Heat-shock proteins in cancer vaccines: agents of antigen cross-presentation. Expert Rev Vaccines. 2008; 7(7):1019-30. DOI: 10.1586/14760584.7.7.1019. View

Srivastava P . Immunotherapy for human cancer using heat shock protein-peptide complexes. Curr Oncol Rep. 2005; 7(2):104-8. DOI: 10.1007/s11912-005-0035-8. View

10.

Kovalchin J, Murthy A, Horattas M, Guyton D, Chandawarkar R . Determinants of efficacy of immunotherapy with tumor-derived heat shock protein gp96. Cancer Immun. 2003; 1:7. View

11.

Apostolopoulos V, Chelvanayagam G, Xing P, McKenzie I . Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules. J Immunol. 1998; 161(2):767-75. View

12.

Arnold D, Faath S, RAMMENSEE H, Schild H . Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med. 1995; 182(3):885-9. PMC: 2192175. DOI: 10.1084/jem.182.3.885. View

13.

Koido S, Nikrui N, Ohana M, Xia J, Tanaka Y, Liu C . Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol Oncol. 2005; 99(2):462-71. DOI: 10.1016/j.ygyno.2005.07.019. View

14.

Udono H, Srivastava P . Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med. 1993; 178(4):1391-6. PMC: 2191193. DOI: 10.1084/jem.178.4.1391. View

15.

Calderwood S, Theriault J, Gong J . Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol. 2005; 35(9):2518-27. DOI: 10.1002/eji.200535002. View

16.

Wang X, Kazim L, Repasky E, Subjeck J . Immunization with tumor-derived ER chaperone grp170 elicits tumor-specific CD8+ T-cell responses and reduces pulmonary metastatic disease. Int J Cancer. 2003; 105(2):226-31. DOI: 10.1002/ijc.11058. View

17.

Belli F, Testori A, Rivoltini L, Maio M, Andreola G, Sertoli M . Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol. 2002; 20(20):4169-80. DOI: 10.1200/JCO.2002.09.134. View

18.

Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E . A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother. 2005; 55(8):958-68. PMC: 11031093. DOI: 10.1007/s00262-005-0084-8. View

19.

Binder R, Srivastava P . Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol. 2005; 6(6):593-9. DOI: 10.1038/ni1201. View

20.

Parmiani G, De Filippo A, Pilla L, Castelli C, Rivoltini L . Heat shock proteins gp96 as immunogens in cancer patients. Int J Hyperthermia. 2006; 22(3):223-7. DOI: 10.1080/02656730600647957. View